Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space

Intercept’s failure to secure FDA approval for obeticholic acid (OCA) tablets in non-alcoholic steatohepatitis shines a light on safety challenges in the space, experts told BioSpace.